AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

ARMOUR Residential REIT, Inc.

$15.47 -$2.62 (-14.48%)
NYSE · 14 Sep 2026 18:44 UTC
Previous Close
$15.8
Day Range
$15.47$15.77
Year Range
$13.98$19.31
Market Cap
1.8B
AVG Volume
3.58M
Trailing/Forward PE
4.15/5.27
PEG ratio
14.76
Dividend Yield
18.62%
Next Earnings Date
2026-10-28
Primary Exchange
New York Stock ExchangeUS
Revenue (USD)
-1B01B2B2016201720182019202020212022202320242025
ARR Revenue (USD) by year
PeriodRevenue (USD)
20251.31B
2024239.9M
2023449.68M
2022-975.17M
2021-92.94M
2020-213.22M
2019212.93M
201835.97M
2017272.27M
2016-207.94M
Net Income (USD)
-400M-200M0200M400M2016201720182019202020212022202320242025
ARR Net Income (USD) by year
PeriodNet Income (USD)
2025322.69M
2024-14.39M
2023-67.92M
2022-229.93M
202115.36M
2020-215.11M
2019-249.91M
2018-110.22M
2017181.15M
2016-45.52M
Operating Income (USD)
-500M0500M1B2016201720182019202020212022202320242025
ARR Operating Income (USD) by year
PeriodOperating Income (USD)
2025964.77M
2024509.75M
2023457.8M
2022-104.96M
202122.47M
2020-211.02M
2019-190.45M
2018-59.82M
2017181.15M
2016-48.98M
EBITDA (USD)
-500M0500M1B2016201720182019202020212022202320242025
ARR EBITDA (USD) by year
PeriodEBITDA (USD)
2025967.23M
2024509.75M
2023458.92M
2022-85.95M
202186.37M
2020-84.52M
201945.61M
201896.29M
2017273.69M
201677.5M
Cash Flows (USD)
-400M-200M0200M400M2016201720182019202020212022202320242025
ARR Cash Flows (USD) by year
PeriodCash Flows (USD)
2025124.2M
2024261.46M
2023132.82M
2022124.08M
202111.74M
2020-257.82M
2019-40.72M
201875.22M
2017110.08M
2016-203.43M
EPS (USD)
-40-20020402016201720182019202020212022202320242025
ARR EPS (USD) by year
PeriodEPS (USD)
20252.73
2024-0.55
2023-1.89
2022-11.36
20210.91
2020-20.53
2019-23.32
2018-14.34
201720.68
2016-8.44
Expenses (USD)
0500K1M1.5M2M2016201720182019202020212022202320242025
ARR Expenses (USD) by year
PeriodExpenses (USD)
20250
20240
20230
20220
20210
20200
20190
20180
20170
20161.55M
Cash & Debt (USD)
05B10B15B20BCashShort Term Debt2016201720182019202020212022202320242025
ARR Cash & Debt (USD) by year
PeriodCash & Debt (USD)
2025289.97M
202467.97M
2023258.86M
2022118.09M
2021356.22M
2020171.67M
2019273.17M
20187.27B
20177.74B
20166.78B
Debt ratios
-200-150-100-5005020182019202020212022202320242025
ARR Debt ratios by year
PeriodDebt ratios
20259.54
2024-0.07
202325.05
2022-164.85
202124.99
202013.18
201922.47
2018-0.6
Margins
0%50%100%150%2016201720182019202020212022202320242025
ARR Margins by year
PeriodMargins
202597.02%
202486.19%
202392.99%
2022102.66%
2021124.22%
2020109.74%
201986.11%
201824.26%
201790.24%
2016106.27%
Return on Capital
-30%-20%-10%0%10%20%2016201720182019202020212022202320242025
ARR Return on Capital by year
PeriodReturn on Capital
202514.27%
2024-1.06%
2023-5.34%
2022-20.67%
20211.34%
2020-22.93%
2019-17.39%
2018-9.8%
201713.66%
2016-4.17%
Shares Outstanding
050M100M150M2016201720182019202020212022202320242025
ARR Shares Outstanding by year
PeriodShares Outstanding
2025112.24M
202452.16M
202348.89M
202232.58M
202118.34M
202012.98M
201911.78M
20188.53M
20178.37M
20167.34M
Dividends (USD)
0510152017201820192020202120222023202420252026
ARR Dividends (USD) by year
PeriodDividends (USD)
20262.16
20252.88
20242.88
20235
20226
20216
20206
201910.8
201811.4
201711.4
Employee Count
01020302016201720182019202020212022202320242025
ARR Employee Count by year
PeriodEmployee Count
202520
202420
202322
202221
202123
202022
201923
201821
201719
201619
Book Value Per Share (USD)
0501001502002016201720182019202020212022202320242025
ARR Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
202520.14
202426.1
202326
202234.14
202162.35
202072.28
2019121.93
2018131.88
2017158.41
2016148.72
Total Assets (USD)
010B20B30B2016201720182019202020212022202320242025
ARR Total Assets (USD) by year
PeriodTotal Assets (USD)
202521.01B
202413.55B
202312.34B
20229.44B
20215.28B
20205.52B
201913.27B
20188.46B
20178.93B
20167.98B
PE Ratio
0204060med 7.39Oct 21Jan 22Nov 24Oct 25Feb 26May 26Sep 26
ARR PE Ratio by year
PeriodPE Ratio
Sep 264.73
Sep 264.9
Aug 264.89
Aug 264.9
Aug 265.02
Aug 265
Jul 264.94
Jul 264.88
Jul 268.26
Jul 268.48
Jul 268.52
Jun 268.58
Jun 268.33
Jun 268.5
Jun 268.51
May 268.53
May 268.24
May 268.44
May 268.77
May 268.82
Apr 268.76
Apr 266.14
Apr 266.15
Apr 265.96
Mar 265.47
Mar 265.38
Mar 265.94
Mar 266.16
Feb 266.24
Feb 266.22
Feb 2629.58
Feb 2628.59
Jan 2628.12
Jan 2629.67
Jan 2630.9
Jan 2629.25
Jan 2629.24
Dec 2528.33
Dec 2528.12
Dec 2527.33
Dec 2528.41
Nov 2528.32
Nov 2526.85
Nov 2526.98
Nov 2527.2
Oct 2526.22
Oct 2526.52
Feb 257.38
Jan 257.38
Jan 257.26
Jan 257.32
Jan 257.18
Jan 257.56
Dec 247.33
Dec 247.39
Dec 247.6
Dec 247.57
Nov 247.42
Nov 247.33
Nov 247.38
Nov 247.57
Nov 247.29
Oct 247.6
Apr 2244.35
Apr 2247.52
Apr 2248.83
Apr 2250.26
Mar 2250.32
Mar 2250.08
Mar 2251.16
Mar 2249.37
Feb 2248.77
Feb 2252.05
Feb 226.39
Feb 226.51
Jan 226.57
Jan 226.6
Jan 226.95
Jan 227.2
Dec 217.01
Dec 217.03
Dec 216.8
Dec 217.19
Dec 217.01
Nov 217.12
Nov 217.36
Nov 217.49
Nov 217.77
Oct 217.52
Oct 215.48
Oct 215.51
Oct 215.62
Oct 215.61
Sep 215.55
Sep 215.54
Sep 215.59
Sep 215.59
Aug 215.61
Aug 215.39
Aug 215.43
Free Cash Flow Yield
0%10%20%30%40%med 20.02%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ARR Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 2615.66%
Sep 2615.13%
Aug 2615.16%
Aug 2615.14%
Aug 2614.78%
Aug 2614.83%
Jul 2615.02%
Jul 2615.21%
Jul 266.76%
Jul 266.59%
Jul 266.56%
Jun 266.51%
Jun 266.7%
Jun 266.57%
Jun 266.56%
May 266.55%
May 266.78%
May 266.61%
May 266.37%
May 266.33%
Apr 266.37%
Apr 266.27%
Apr 266.26%
Apr 266.46%
Mar 267.03%
Mar 267.15%
Mar 266.48%
Mar 266.25%
Feb 266.16%
Feb 266.19%
Feb 269.38%
Feb 269.7%
Jan 269.87%
Jan 269.35%
Jan 268.98%
Jan 269.48%
Jan 269.49%
Dec 259.79%
Dec 259.87%
Dec 2510.15%
Dec 259.77%
Nov 259.8%
Nov 2510.34%
Nov 2510.29%
Nov 2510.2%
Oct 2510.58%
Oct 2510.46%
Oct 2520.12%
Oct 2520.14%
Oct 2520.34%
Sep 2521.62%
Sep 2521.59%
Sep 2520.56%
Sep 2519.91%
Aug 2520.58%
Aug 2520.74%
Aug 2520.92%
Aug 2520.17%
Aug 2519.23%
Jul 2518.69%
Jul 2521.47%
Jul 2521%
Jul 2520.98%
Jun 2521.34%
Jun 2521.49%
Jun 2521.12%
Jun 2521.39%
May 2521.83%
May 2522.14%
May 2521.05%
May 2521%
May 2521.81%
Apr 2522.13%
Apr 2535.05%
Apr 2535.58%
Apr 2533.26%
Mar 2529.4%
Mar 2527.05%
Mar 2526.66%
Mar 2526.37%
Feb 2526.31%
Feb 2526.54%
Feb 2526.14%
Feb 2523.82%
Jan 2523.8%
Jan 2524.2%
Jan 2524.01%
Jan 2524.45%
Jan 2523.25%
Dec 2423.97%
Dec 2423.76%
Dec 2423.11%
Dec 2423.2%
Nov 2423.68%
Nov 2423.97%
Nov 2423.82%
Nov 2423.2%
Nov 2424.1%
Oct 2423.1%
Oct 2421.29%
Price to Sales
012345med 2.06Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ARR Price to Sales by year
PeriodPrice to Sales
Sep 262.02
Sep 262.09
Aug 262.09
Aug 262.09
Aug 262.14
Aug 262.13
Jul 262.11
Jul 262.08
Jul 262
Jul 262.05
Jul 262.06
Jun 262.08
Jun 262.02
Jun 262.06
Jun 262.06
May 262.07
May 262
May 262.04
May 262.12
May 262.14
Apr 262.12
Apr 261.52
Apr 261.52
Apr 261.47
Mar 261.35
Mar 261.33
Mar 261.47
Mar 261.52
Feb 261.54
Feb 261.54
Feb 262.6
Feb 262.51
Jan 262.47
Jan 262.61
Jan 262.72
Jan 262.57
Jan 262.57
Dec 252.49
Dec 252.47
Dec 252.4
Dec 252.5
Nov 252.49
Nov 252.36
Nov 252.37
Nov 252.39
Oct 252.31
Oct 252.33
Oct 251.75
Oct 251.74
Oct 251.73
Sep 251.62
Sep 251.63
Sep 251.71
Sep 251.76
Aug 251.71
Aug 251.69
Aug 251.68
Aug 251.74
Aug 251.83
Jul 251.88
Jul 252.09
Jul 252.14
Jul 252.14
Jun 252.1
Jun 252.09
Jun 252.12
Jun 252.1
May 252.05
May 252.03
May 252.13
May 252.14
May 252.06
Apr 252.03
Apr 253.11
Apr 253.06
Apr 253.28
Mar 253.71
Mar 254.03
Mar 254.09
Mar 254.13
Feb 254.14
Feb 254.11
Feb 254.17
Feb 250.96
Jan 250.96
Jan 250.94
Jan 250.95
Jan 250.93
Jan 250.98
Dec 240.95
Dec 240.96
Dec 240.99
Dec 240.98
Nov 240.96
Nov 240.95
Nov 240.96
Nov 240.98
Nov 240.95
Oct 240.99
Oct 243.4
EV/EBITDA
0102030med 2.33Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ARR EV/EBITDA by year
PeriodEV/EBITDA
Sep 2621.53
Sep 2621.6
Aug 2621.6
Aug 2621.6
Aug 2621.65
Aug 2621.64
Jul 2621.61
Jul 2621.59
Jul 2626.67
Jul 2626.74
Jul 2626.75
Jun 2626.77
Jun 2626.69
Jun 2626.75
Jun 2626.75
May 2626.75
May 2626.66
May 2626.73
May 2626.83
May 2626.85
Apr 2626.83
Apr 2620.3
Apr 2620.3
Apr 2620.24
Mar 2620.08
Mar 2620.05
Mar 2620.23
Mar 2620.31
Feb 2620.33
Feb 2620.33
Feb 262.82
Feb 262.73
Jan 262.68
Jan 262.83
Jan 262.95
Jan 262.79
Jan 262.79
Dec 252.7
Dec 252.68
Dec 252.6
Dec 252.71
Nov 252.7
Nov 252.56
Nov 252.57
Nov 252.59
Oct 252.5
Oct 252.53
Oct 252.25
Oct 252.25
Oct 252.22
Sep 252.07
Sep 252.08
Sep 252.2
Sep 252.28
Aug 252.19
Aug 252.17
Aug 252.15
Aug 252.24
Aug 252.37
Jul 252.44
Jul 252.28
Jul 252.33
Jul 252.33
Jun 252.29
Jun 252.27
Jun 252.32
Jun 252.29
May 252.24
May 252.2
May 252.32
May 252.33
May 252.24
Apr 252.21
Apr 251.33
Apr 251.31
Apr 251.41
Mar 251.61
Mar 251.76
Mar 251.79
Mar 251.81
Feb 251.82
Feb 251.8
Feb 251.83
Feb 251.38
Jan 251.38
Jan 251.36
Jan 251.37
Jan 251.34
Jan 251.42
Dec 241.37
Dec 241.39
Dec 241.43
Dec 241.42
Nov 241.39
Nov 241.37
Nov 241.38
Nov 241.42
Nov 241.37
Oct 241.43
Oct 241.99
Price/Operating Cashflow
05101520med 5Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ARR Price/Operating Cashflow by year
PeriodPrice/Operating Cashflow
Sep 266.39
Sep 266.61
Aug 266.6
Aug 266.6
Aug 266.77
Aug 266.74
Jul 266.66
Jul 266.58
Jul 2614.79
Jul 2615.18
Jul 2615.26
Jun 2615.37
Jun 2614.93
Jun 2615.23
Jun 2615.24
May 2615.27
May 2614.76
May 2615.12
May 2615.7
May 2615.79
Apr 2615.69
Apr 2615.94
Apr 2615.97
Apr 2615.49
Mar 2614.22
Mar 2613.99
Mar 2615.44
Mar 2616
Feb 2616.22
Feb 2616.17
Feb 2610.66
Feb 2610.3
Jan 2610.14
Jan 2610.69
Jan 2611.14
Jan 2610.54
Jan 2610.54
Dec 2510.21
Dec 2510.14
Dec 259.85
Dec 2510.24
Nov 2510.21
Nov 259.68
Nov 259.72
Nov 259.8
Oct 259.45
Oct 259.56
Oct 254.97
Oct 254.96
Oct 254.92
Sep 254.62
Sep 254.63
Sep 254.86
Sep 255.02
Aug 254.86
Aug 254.82
Aug 254.78
Aug 254.96
Aug 255.2
Jul 255.35
Jul 254.66
Jul 254.76
Jul 254.77
Jun 254.69
Jun 254.65
Jun 254.73
Jun 254.68
May 254.58
May 254.52
May 254.75
May 254.76
May 254.58
Apr 254.52
Apr 252.85
Apr 252.81
Apr 253.01
Mar 253.4
Mar 253.7
Mar 253.75
Mar 253.79
Feb 253.8
Feb 253.77
Feb 253.83
Feb 254.2
Jan 254.2
Jan 254.13
Jan 254.17
Jan 254.09
Jan 254.3
Dec 244.17
Dec 244.21
Dec 244.33
Dec 244.31
Nov 244.22
Nov 244.17
Nov 244.2
Nov 244.31
Nov 244.15
Oct 244.33
Oct 244.7
Price to Book
0.50.60.70.80.91med 0.79Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ARR Price to Book by year
PeriodPrice to Book
Sep 260.79
Sep 260.82
Aug 260.82
Aug 260.82
Aug 260.84
Aug 260.84
Jul 260.82
Jul 260.81
Jul 260.85
Jul 260.87
Jul 260.88
Jun 260.88
Jun 260.86
Jun 260.87
Jun 260.88
May 260.88
May 260.85
May 260.87
May 260.9
May 260.91
Apr 260.9
Apr 260.88
Apr 260.88
Apr 260.85
Mar 260.78
Mar 260.77
Mar 260.85
Mar 260.88
Feb 260.89
Feb 260.89
Feb 260.9
Feb 260.87
Jan 260.85
Jan 260.9
Jan 260.94
Jan 260.89
Jan 260.89
Dec 250.86
Dec 250.85
Dec 250.83
Dec 250.86
Nov 250.86
Nov 250.81
Nov 250.82
Nov 250.82
Oct 250.79
Oct 250.8
Oct 250.79
Oct 250.79
Oct 250.78
Sep 250.74
Sep 250.74
Sep 250.77
Sep 250.8
Aug 250.77
Aug 250.77
Aug 250.76
Aug 250.79
Aug 250.83
Jul 250.85
Jul 250.73
Jul 250.74
Jul 250.74
Jun 250.73
Jun 250.73
Jun 250.74
Jun 250.73
May 250.72
May 250.71
May 250.74
May 250.74
May 250.72
Apr 250.71
Apr 250.55
Apr 250.54
Apr 250.58
Mar 250.65
Mar 250.71
Mar 250.72
Mar 250.73
Feb 250.73
Feb 250.72
Feb 250.73
Feb 250.74
Jan 250.74
Jan 250.73
Jan 250.73
Jan 250.72
Jan 250.76
Dec 240.73
Dec 240.74
Dec 240.76
Dec 240.76
Nov 240.74
Nov 240.73
Nov 240.74
Nov 240.76
Nov 240.73
Oct 240.76
Oct 240.86
ARMOUR Residential REIT, Inc.
ARR
Stockpicker

Video analysis: ARR

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ARR

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

gurufocus.com · 13 Sep 2026

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positi

6 Ultra-High-Yield Names Where Coverage Is Cracking

247wallst.com · 12 Sep 2026

6 Ultra-High-Yield Names Where Coverage Is Cracking

A 29% yield sounds like a retirement dream until you look at what the coverage math actually says. Six popular high-yield names are flashing warning signs that patient investors can no longer afford to ignore.

A $500,000 Roth Portfolio Loaded With High-Yield Dividend Stocks Pays $40,000 a Year and the IRS Gets None of It

247wallst.com · 11 Sep 2026

A $500,000 Roth Portfolio Loaded With High-Yield Dividend Stocks Pays $40,000 a Year and the IRS Gets None of It

Mortgage REITs like ORC, ARR, and AGNC throw off some of the fattest yields on the market, but where you hold them determines whether the IRS quietly pockets a quarter of every distribution before it ever reaches you.

The Hidden Problem With These High-Yield Mortgage REIT Distributions

247wallst.com · 11 Sep 2026

The Hidden Problem With These High-Yield Mortgage REIT Distributions

Some of the highest-yielding mortgage REITs on the market are quietly handing investors back their own money while calling it income.

SpaceX Closes $1.11 Billion-a-Month Compute Deal as CFO Doubles Down on $100 Billion ARR Target

benzinga.com · 11 Sep 2026

SpaceX Closes $1.11 Billion-a-Month Compute Deal as CFO Doubles Down on $100 Billion ARR Target

Space Exploration Technologies Corp.‘s (NASDAQ:SPCX) Chief Financial Officer Bret Johnsen says the company has closed another compute agreement that would help the Elon Musk-led space giant reach its intended $100 billion ARR target by year-end.

Is Adobe Inc (ADBE) Undervalued After Q3 Earnings Beat? EPS at $4.62, Revenue at $6.76 Billion -- GF Score: 86/100

gurufocus.com · 10 Sep 2026

Is Adobe Inc (ADBE) Undervalued After Q3 Earnings Beat? EPS at $4.62, Revenue at $6.76 Billion -- GF Score: 86/100

Adobe Inc (ADBE) released its 8-K filing on September 10, 2026, detailing impressive financial results for the third quarter of fiscal year 2026. The company's

The Dividend Trap: These Mortgage REITs Paid Investors While Destroying Principal

247wallst.com · 10 Sep 2026

The Dividend Trap: These Mortgage REITs Paid Investors While Destroying Principal

Mortgage REITs are flashing double-digit yields right now, but for some of the biggest names in the sector, those payouts have been quietly funded by eroding the very principal they promised to protect.

American Rare Earths Appoints Dr. Sanja Miskovic as Chief Technical Advisor

globenewswire.com · 10 Sep 2026

American Rare Earths Appoints Dr. Sanja Miskovic as Chief Technical Advisor

Appointment strengthens feasibility study execution and advances ARR's pathway to producing separated rare earth oxides in Wyoming Appointment strengthens feasibility study execution and advances ARR's pathway to producing separated rare earth oxides in Wyoming

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.